Antiepileptic drugs increase plasma levels of 4beta-hydroxycholesterol in humans: evidence for involvement of cytochrome p450 3A4.

The major cholesterol oxidation products in the human circulation are 27-hydroxycholesterol, 24-hydroxycholesterol, and 7alpha-hydroxycholesterol. These oxysterols are formed from cholesterol by specific cytochrome P450 enzymes, CYP27, CYP46, and CYP7A, respectively. An additional oxysterol present in concentrations comparable with 7alpha- and 24-hydroxycholesterol is 4beta-hydroxycholesterol. We now report that patients treated with the antiepileptic drugs phenobarbital, carbamazepine, or phenytoin have highly elevated levels of plasma 4beta-hydroxycholesterol. When patients with uncomplicated cholesterol gallstone disease were treated with ursodeoxycholic acid, plasma 4beta-hydroxycholesterol increased by 45%. Ursodeoxycholic acid, as well as the antiepileptic drugs, are known to induce cytochrome P450 3A. Recombinant CYP3A4 was shown to convert cholesterol to 4beta-hydroxycholesterol, whereas no conversion was observed with CYP1A2, CYP2C9, or CYP2B6. The concentration of 4alpha-hydroxycholesterol in plasma was lower than the concentration of 4beta-hydroxycholesterol and not affected by treatment with the antiepileptic drugs or ursodeoxycholic acid. Together, these data suggest that 4beta-hydroxycholesterol in human circulation is formed by a cytochrome P450 enzyme.

• Publication year

  2001

• Venue

  Journal of Biological Chemistry

• Publication date

  2001-10-19

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1074/JBC.M105127200PMID 11514559
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cytochromes P450 and metabolism of xenobiotics

  2001cited by this paper
• Apoptosis of vascular smooth muscle cells induced by cholesterol and its oxides in vitro and in vivo.

  2000cited by this paper
• Role of LXRs in control of lipogenesis.

  2000cited by this paper
• Dexamethasone enhances constitutive androstane receptor expression in human hepatocytes: consequences on cytochrome P450 gene regulation.

  2000cited by this paper
• Oxysterols: modulators of cholesterol metabolism and other processes.

  2000cited by this paper
• Oxysterol biosynthetic enzymes.

  2000cited by this paper
• cDNA cloning of cholesterol 24-hydroxylase, a mediator of cholesterol homeostasis in the brain.

  1999cited by this paper
• Clinically significant pharmacokinetic drug interactions between antiepileptic drugs

  1999cited by this paper
• Structural requirements of ligands for the oxysterol liver X receptors LXRalpha and LXRbeta.

  1999cited by this paper
• Bile acid structure and selective modulation of murine hepatic cytochrome P450–linked enzymes

  1999cited by this paper
• Update: Clinically Significant Cytochrome P‐450 Drug Interactions

  1998cited by this paper
• The oxysterols cholest-5-ene-3β,4α-diol, cholest-5-ene-3β,4β-diol and cholestane-3β,5α,6α-triol are formed during in vitro oxidation of low density lipoprotein, and are present in human atherosclerotic plaques

  1996cited by this paper
• An oxysterol signalling pathway mediated by the nuclear receptor LXRα

  1996cited by this paper
• The oxysterols cholest-5-ene-3 beta,4 alpha-diol, cholest-5-ene-3 beta,4 beta-diol and cholestane-3 beta,5 alpha,6 alpha-triol are formed during in vitro oxidation of low density lipoprotein, and are present in human atherosclerotic plaques.

  1996cited by this paper
• Oxysterols induced apoptosis in cultured smooth muscle cells through CPP32 protease activation and bcl-2 protein downregulation.

  1996cited by this paper
• Determination of cholesterol oxidation products in human plasma by isotope dilution-mass spectrometry.

  1995cited by this paper
• Identification and quantitation of cholest-5-ene-3 beta,4 beta-diol in rat liver and human plasma.

  1995cited by this paper
• Geographical/Interracial Differences in Polymorphic Drug Oxidation

  1995cited by this paper
• Cholesterol and 27-hydroxycholesterol 7 alpha-hydroxylation: evidence for two different enzymes.

  1993cited by this paper
• Cloning of the human cholesterol 7 alpha-hydroxylase gene (CYP7) and localization to chromosome 8q11-q12.

  1992cited by this paper
• Characterization of human sterol 27-hydroxylase. A mitochondrial cytochrome P-450 that catalyzes multiple oxidation reaction in bile acid biosynthesis.

  1991cited by this paper
• Identification of 3 alpha,4 beta,7 alpha-trihydroxy-5 beta-cholanoic acid in human bile: reflection of a new pathway in bile acid metabolism in humans.

  1989cited by this paper
• Hepatic bile acid metabolism during early development revealed from the analysis of human fetal gallbladder bile.

  1988cited by this paper
• Serum cholesterol determination by mass fragmentography.

  1974cited by this paper
• The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum.

  1955cited by this paper

• 4β-Hydroxycholesterol as an endogenous biomarker for CYP3A induction: Scientific rationale, clinical utility, and future perspectives.

  2026cites this paper
• Hepatoprotective Effects of Cilnidipine in Cholestatic Liver Disease: Role of FXR and NRF2 Signalling

  2025cites this paper
• Role of oxysterol 4β-hydroxycholesterol and liver X receptor alleles in pre-eclampsia

  2025cites this paper
• Nuclear Receptors CAR and PXR as Cardiometabolic Regulators.

  2025cites this paper
• Synergistic action of cilnidipine and bexarotene in mitigating cholestatic liver damage: role of FXR signaling cascade

  2025cites this paper
• Novel insights into bexarotene's role in preventing cholestasis: mechanisms and implications

  2025cites this paper
• Gene Polymorphisms of NLRP3 Associated With Plasma Levels of 4β‐Hydroxycholesterol, an Endogenous Marker of CYP3A Activity, in Patients With Asthma

  2024cites this paper
• Protective effect of alpha-tocopherol on lipogenesis and oxysterol production in hypercholesterolemia-induced nonalcoholic steatohepatitis

  2024cites this paper
• Investigation of pharmacokinetic drug interaction between clesacostat and DGAT2 inhibitor ervogastat in healthy adult participants

  2024cites this paper
• Applications of the Cholesterol Metabolite, 4β-Hydroxycholesterol, as a Sensitive Endogenous Biomarker for Hepatic CYP3A Activity Evaluated within a PBPK Framework

  2024influential citation
• Evaluation of the usefulness of plasma 4β‐hydroxycholesterol concentration normalized by 4α‐hydroxycholesterol for accurate CYP3A phenotyping

  2024influential citation
• Clinical Evaluation Based on a New Approach to Improve the Accuracy of 4β-Hydroxycholesterol Measurement as a Biomarker of CYP3A4 Activity

  2023cites this paper
• Evaluation of effects of indoxyl sulfate and parathyroid hormone on CYP3A activity considering the influence of CYP3A5 gene polymorphisms

  2023cites this paper
• Comparison of 1Beta- and 5Beta-hydroxylation of Deoxycholate and Glycodeoxycholate as In Vitro Index Reactions for Cytochrome P450 3A Activities

  2023cites this paper
• Novel Approaches to Characterize Individual Drug Metabolism and Advance Precision Medicine

  2023cites this paper
• A diet supplemented with cholic acid elevates blood pressure accompanied by albuminuria in rats.

  2023cites this paper
• Insulin dysregulation drives mitochondrial cholesterol metabolite accumulation: initiating hepatic toxicity in nonalcoholic fatty liver disease

  2023cites this paper
• Interactions Between Direct Oral Anticoagulants (DOACs) and Antiseizure Medications: Potential Implications on DOAC Treatment

  2023cites this paper
• Identification and in vivo detection of side-chain hydroxylated metabolites of 4β-hydroxycholesterol.

  2023cites this paper
• Prediction of pyrotinib exposure based on physiologically-based pharmacokinetic model and endogenous biomarker

  2022cites this paper
• Investigation of CYP3A induction by PF‐05251749 in early clinical development: comparison of linear slope physiologically based pharmacokinetic prediction and biomarker response

  2022cites this paper
• Association of demographic and health characteristics with circulating oxysterol concentrations.

  2022cites this paper
• Nuclear Receptors and Lipid Sensing.

  2022cites this paper
• Evaluation of hepatic CYP3A enzyme activity using endogenous markers in lung cancer patients treated with cisplatin, dexamethasone, and aprepitant

  2022cites this paper
• Sensitive UHPLC-MS/MS quantification method for 4β- and 4α-hydroxycholesterol in plasma for accurate CYP3A phenotyping

  2022cites this paper
• Design and conduct considerations for studies in patients with hepatic impairment

  2022cites this paper
• Correlations between 4β-hydroxycholesterol and hepatic and intestinal CYP3A4: protein expression, microsomal ex vivo activity, and in vivo activity in patients with a wide body weight range

  2022cites this paper
• CYP3A Activity in End-of-Life Cancer Patients Measured by 4β-Hydroxycholesterol/cholesterol Ratio, in Men and Women

  2021cites this paper
• Cardioprotective effects of amiodarone in a rat model of epilepsy‐induced cardiac dysfunction

  2021cites this paper
• Tertiary Oxidation of Deoxycholate Is Predictive of CYP3A Activity in Dogs

  2021cites this paper
• The utility of endogenous glycochenodeoxycholate-3-sulfate and 4β-hydroxycholesterol to evaluate the hepatic disposition of atorvastatin in rats

  2021cites this paper
• Relationship of hemoglobin level and plasma coproporphyrin‐I concentrations as an endogenous probe for phenotyping OATP1B

  2021cites this paper
• The Biosynthesis of Enzymatically Oxidized Lipids

  2020cites this paper
• Pregnane X Receptor Activator Rifampin Increases Blood Pressure and Stimulates Plasma Renin Activity

  2020cites this paper
• Inhibition and induction of CYP enzymes in humans: an update

  2020cites this paper
• 4β-Hydroxycholesterol is a prolipogenic factor that promotes SREBP1c expression and activity through the liver X receptor

  2020cites this paper
• Toxicity and pharmacokinetic biomarkers for personalized non-small cell lung cancer treatment

  2020cites this paper
• Use of endogenous cholesterol and its metabolite as markers of cyp450 metabolic activity

  2020cites this paper
• 4β-Hydroxycholesterol Signals From the Liver to Regulate Peripheral Cholesterol Transporters

  2020cites this paper
• Oxysterols and Bile Acid Act as Signaling Molecules That Regulate Cholesterol Homeostasis: Nuclear Receptors LXR, FXR, and Fibroblast Growth Factor 15/19

  2020cites this paper
• Cytochrome P450 Metabolism Leads to Novel Biological Sterols and Other Steroids

  2020cites this paper
• 12α-hydroxylated bile acid induces hepatic steatosis with dysbiosis in rats.

  2020cites this paper
• Assessment of effects of repeated oral doses of fedratinib on inhibition of cytochrome P450 activities in patients with solid tumors using a cocktail approach

  2020cites this paper
• Inherited and Acquired Determinants of Hepatic CYP3A Activity in Humans

  2020cites this paper
• A first-in-human study of the novel metabolism-based anti-cancer agent SM-88 in subjects with advanced metastatic cancer

  2019cites this paper
• Phenotyping of Human CYP450 Enzymes by Endobiotics: Current Knowledge and Methodological Approaches

  2019cites this paper
• Use of 4β‐Hydroxycholesterol Plasma Concentrations as an Endogenous Biomarker of CYP3A Activity: Clinical Validation in Individuals With Type 2 Diabetes

  2019cites this paper
• Modeling and simulation of the endogenous CYP3A induction marker 4β-hydroxycholesterol during enasidenib treatment

  2019cites this paper
• Formation and metabolism of oxysterols and cholestenoic acids found in the mouse circulation: Lessons learnt from deuterium-enrichment experiments and the CYP46A1 transgenic mouse

  2019cites this paper
• The transcription factor E4bp4 regulates the expression and activity of Cyp3a11 in mice

  2019cites this paper
• 4β‐Hydroxycholesterol as an Endogenous Biomarker for CYP3A Activity: Literature Review and Critical Evaluation

  2019cites this paper
• A comparative study for detecting CYP3A induction by CYP3A probe drugs and endogenous markers in cynomolgus monkeys

  2019cites this paper
• Effect of ursodeoxycholic acid in facilitating early hepatic clearance of radiotracer among patients undergoing 99mTc-sestamibi myocardial perfusion scintigraphy: A randomized double blind placebo controlled parallel trial

  2019cites this paper
• Effect of Grapefruit Juice Intake on Serum Level of the Endogenous CYP3A4 Metabolite 4β-Hydroxycholesterol—an Interaction Study in Healthy Volunteers

  2019cites this paper
• Kratom-Induced Cholestatic Liver Injury and Its Conservative Management

  2019cites this paper
• Oxysterols: Cellular Effects and Relations with Chronical Diseases

  2019cites this paper
• Solving the interactions of steroidal ligands with CYP3A4 using a grid-base template system.

  2019cites this paper
• Relationships between endogenous CYP3A markers and plasma amlodipine exposure and metabolism in early postpartum and non-peripartum women with hypertension.

  2019cites this paper
• Factors involved in phenoconversion of CYP3A using 4β-hydroxycholesterol in stable kidney transplant recipients

  2019cites this paper
• Inflammation down-regulates CYP3A4-catalysed drug metabolism in hemodialysis patients

  2018cites this paper
• The occurrence of metabolic and inflammatory causes of psychosis in admissions to a psychiatric unit

  2018influential citation
• Importance of genetic background of oxysterol signaling in cancer.

  2018cites this paper
• Associations between Cytokine Levels and CYP3A4 Phenotype in Patients with Rheumatoid Arthritis

  2018cites this paper
• Quantitative analysis of 4β- and 4α‑hydroxycholesterol in human plasma and serum by UHPLC/ESI-HR-MS.

  2018cites this paper
• Simultaneous Physiologically Based Pharmacokinetic (PBPK) Modeling of Parent and Active Metabolites to Investigate Complex CYP3A4 Drug-Drug Interaction Potential: A Case Example of Midostaurin

  2018cites this paper
• Drug Response And Metabolism In Crohn's Disease

  2018cites this paper
• Evaluation of 4β-Hydroxycholesterol and 25-Hydroxycholesterol as Endogenous Biomarkers of CYP3A4: Study with CYP3A-Humanized Mice

  2018cites this paper
• Comparison of CYP3A4-Inducing Capacity of Enzyme-Inducing Antiepileptic Drugs Using 4&bgr;-Hydroxycholesterol as Biomarker

  2018cites this paper
• Differences in the Serum 4β-hydroxycholesterol Levels of Patients with Chronic Hepatitis C Virus (HCV) Infection: A Possible Impact on the Efficacy and Safety of Interferon (IFN)-free Treatment

  2017influential citation
• 1 Overview of Targeted Quantitation of Biomarkers and Its Applications

  2017cites this paper
• An Exposure‐Response Modeling Approach to Examine the Relationship Between Potency of CYP3A Inducer and Plasma 4β‐Hydroxycholesterol in Healthy Subjects

  2017cites this paper
• Recovery of CYP3A Phenotype after Kidney Transplantation

  2017influential citation
• Pretransplant 4&bgr;‐hydroxycholesterol does not predict tacrolimus exposure or dose requirements during the first days after kidney transplantation

  2017cites this paper
• 4&bgr;‐Hydroxycholesterol level significantly correlates with steady‐state serum concentration of the CYP3A4 substrate quetiapine in psychiatric patients

  2017cites this paper
• The CYP3A biomarker 4&bgr;‐hydroxycholesterol does not improve tacrolimus dose predictions early after kidney transplantation

  2017cites this paper
• 7-Ketocholesterol is increased in the plasma of X-ALD patients and induces peroxisomal modifications in microglial cells: Potential roles of 7-ketocholesterol in the pathophysiology of X-ALD.

  2017cites this paper
• Examination of the Human Cytochrome P4503A4 Induction Potential of PF-06282999, an Irreversible Myeloperoxidase Inactivator: Integration of Preclinical, In Silico, and Biomarker Methodologies in the Prediction of the Clinical Outcome

  2017cites this paper
• Overview of Targeted Quantitation of Biomarkers and Its Applications

  2017cites this paper
• Managing the Risk of CYP3A Induction in Drug Development: A Strategic Approach

  2017cites this paper
• Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial

  2017cites this paper
• Betydning av alder for kjønnsforskjeller i CYP3A4-fenotype hos pasienter behandlet med eller uten enzyminduserende antiepileptika

  2017influential citation
• Perspective: 4β-hydroxycholesterol as an emerging endogenous biomarker of hepatic CYP3A

  2017cites this paper
• Trace-level determination of eight cholesterol oxidation products in human plasma by dispersive liquid–liquid microextraction and ultra-performance liquid chromatography–tandem mass spectrometry

  2017cites this paper
• Differences in the Serum 4β-hydroxycholesterol Levels of Patients with Chronic HCV Infection: A Possible Impact on the Efficacy and Safety of IFN-free Treatment

  2017cites this paper
• Targeted Biomarker Quantitation by LC-MS

  2017cites this paper
• 4β‐Hydroxycholesterol Level in Patients With Rheumatoid Arthritis Before vs. After Initiation of bDMARDs and Correlation With Inflammatory State

  2016cites this paper
• Impact of genetic and nongenetic factors on interindividual variability in 4β-hydroxycholesterol concentration

  2016cites this paper
• CLINICAL STUDIES OF CYP 3 A 4 AND P-GLYCOPROTEIN

  2016cites this paper
• Use of 4β-hydroxycholesterol in animal and human plasma samples as a biomarker for CYP3A induction.

  2016cites this paper
• Effect of Statin Treatment on Plasma 4β-Hydroxycholesterol Concentrations.

  2016cites this paper
• Relationships between Endogenous Plasma Biomarkers of Constitutive Cytochrome P450 3A Activity and Single‐Time‐Point Oral Midazolam Microdose Phenotype in Healthy Subjects

  2016cites this paper
• PHARMACOKINETICS Comparative performance of oral midazolam clearance and plasma 4 β -hydroxycholesterol to explain interindividual variability in tacrolimus clearance

  2016cites this paper
• New methods for analysis of oxysterols and related compounds by LC-MS.

  2016cites this paper
• Mining the Arabidopsis genome for cytochrome P450 biocatalysts

  2016cites this paper
• The effect of Cyp3a deficiency on the hepatic cholesterol synthesis and prostatic androgen response in the mouse

  2016influential citation
• Studies of drug disposition in hemodialysis patients : impact of genetics, inflammation and vitamin D

  2016cites this paper
• 4β-hydroxycholesterol correlates with dose but not steady-state concentration of carbamazepine: indication of intestinal CYP3A in biomarker formation?

  2016cites this paper
• Recommendations on the Development of a Bioanalytical Assay for 4β-Hydroxycholesterol, an Emerging Endogenous Biomarker of CYP3A Activity

  2016influential citation
• Interindividual Variability in Cytochrome P450–Mediated Drug Metabolism

  2016cites this paper
• Comparative performance of oral midazolam clearance and plasma 4β-hydroxycholesterol to explain interindividual variability in tacrolimus clearance.

  2016cites this paper